NDA Partners Expert Consultant Ellen Areman, Receives AABB Award for Major Contributions to the Field of Cellular Therapies


News Image

I am honored to receive this award for my work in the exciting field of cellular therapies and look forward to continuing to contribute in any way I can to this rapidly growing field and to supporting companies who are developing new cell therapy and regenerative medicine products.

NDA Partners Chief Executive Officer Earle Martin announced today that Ellen Areman, one of the firm’s prominent Expert Consultants, was recently honored by AABB, formerly the American Association of Blood Banks, with the 2020 Emily Cooley Memorial Award and Lectureship. The award recognizes an individual who has demonstrated teaching ability and has made a major contribution to the field of transfusion medicine or cellular therapies. Ms. Areman was recognized for her pioneering work spanning more than 30 years in the field of cellular therapies and for serving as a role model and teacher to several generations of technologists, clinicians, and researchers.

Throughout her career, Ms. Areman’s contributions to cellular therapies have been numerous including her career at the US Food and Drug Administration’s Office of Cellular, Tissue, and Gene Therapy as an Expert Biologist and Product Reviewer, co-chair of the Cord Blood Standards subgroup of the Center for Biologics Research and Evaluation’s Hematopoietic Stem Cell Task Group, and the FDA- CBER/NIH-NHLBI Cell Therapy Working Group. She was also the coordinator of the cell processing section of the National Institutes of Health’s Clinical Center Department of Transfusion Medicine, and has worked as the Laboratory Manager for both the Georgetown University/ NHLBI (COBLT) Cord Blood Bank and Pediatric Cancer and Stem Cell Research Program, as well as Technical Director of Georgetown’s Cellular Engineering/Molecular and Cellular Hematotherapy Laboratory. She joined NDA Partners as an Expert Consultant in 2015 and provides regulatory strategy and CMC support to companies developing biological products including hematopoietic, immunologic, and stem cell therapies.

“I am honored to receive this award for my work in the exciting field of cellular therapies and look forward to continuing to contribute in any way I can to this rapidly growing field and to supporting companies who are developing new cell therapy and regenerative medicine products,” said Ms. Areman.

Ms. Areman earned her master’s degree in pathology from Georgetown University, bachelor’s degree from The State University of New York at Albany, and specialist certification in blood banking from the National Institutes of Health. She is a member of AABB and a founding member of the International Society for Cell Therapies. She has also published extensively on biological products including serving as editor of Cellular Therapy: Principles, Methods and Regulations.

About NDA Partners

NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact

Earle Martin, Chief Executive Officer

Office: 540-738-2550

MartinEarle@ndapartners.com

Share article on social media or email:

Leave a Reply